Zyryanov, S. K., & Dyakov, I. N. Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy. IRBIS LLC.
Chicago Style (17th ed.) CitationZyryanov, S. K., and I. N. Dyakov. Cost-effectiveness Analysis of Acalabrutinib in Treatment of Patients with Relapsed/refractory Form of Mantle Cell Lymphoma Who Previously Received at Least One Line of Therapy. IRBIS LLC.
MLA (9th ed.) CitationZyryanov, S. K., and I. N. Dyakov. Cost-effectiveness Analysis of Acalabrutinib in Treatment of Patients with Relapsed/refractory Form of Mantle Cell Lymphoma Who Previously Received at Least One Line of Therapy. IRBIS LLC.
Warning: These citations may not always be 100% accurate.